Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Desired Travel Objections Worldwide: Where to Go Straightaway - 2Savvy Cleaning: The 6 Robot Vacuums of 2024
- 3A top Marine shares his secrets to keeping fit at 50
- 4Study casts doubt on potential for life on Jupiter's moon Europa
- 5UAE used military bases in Red Sea region to aid Israel's war against Hamas, leaks reveal
- Could the Star of Bethlehem have actually been a comet?
- Euclid space telescope sees gorgeous cosmic cloud | Space photo of the day for Nov. 18, 2025
- Astronomers spot white dwarf star creating a colorful shockwave
- France to build new nuclear aircraft carrier, Macron says
- Amateur's Manual for Venture Strategies for Tenderfoots
- This is Countdown, CNN’s newsletter covering NASA’s first time sending humans to deep space in over 50 years
- Sophie Kinsella, 'Confessions of a Shopaholic' author, dies at 55 after battle with cancer
- Cases of norovirus are on the rise just in time for the holiday season
- Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
